The milestone is being celebrated as a “huge moment” for rare disease drug development.
The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE: MRK) drugs with potential blockbuster sales. Merck's cholesterol treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results